Israeli startup, ForSight Robotics, to begin clinical trials of its ORYOM™ system as demand for cataract surgery and ophthalmologists outpaces global supply.
ForSight Robotics, the Israeli startup pioneering robotic systems for eye surgery, has secured $125 million in a Series B round led by Eclipse, with participation from an undisclosed strategic investor, the Adani Group, Reiya Ventures, Dr. Fred Moll, and other existing backers. The round brings the company’s total funding to $195 million.
The new investment will accelerate development and clinical trials of the company’s flagship product, the ORYOM™ Platform -the world’s first robotic system purpose-built for ophthalmic surgery. Designed to improve surgical precision and patient outcomes while easing the physical strain on surgeons, the platform is initially targeting cataract procedures and is set to enter first-in-human trials later this year.
ForSight’s response to the global eye care workforce crisis
ForSight Robotics was founded to address a critical healthcare challenge: the growing mismatch between rising demand for eye surgeries and the global shortfall in trained ophthalmologists. Over 600 million people suffer from cataracts globally, yet only 30 million receive surgery annually. In the U.S., four million cataract procedures are performed each year, despite a population that requires far more.
A declining global workforce compounds the situation. With only 14.1 cataract surgeons and 31.7 ophthalmologists per million people worldwide, the shortage is expected to worsen by 2035, with a projected 12% drop in ophthalmologists even as patient demand increases by 24%.
Co-founder and Chief Medical Officer Dr. Joseph Nathan said, “We see ophthalmology as the next frontier in the robotics revolution -much like general surgery before the rise of Intuitive Surgical. Our goal is to bring transformative impact to eye surgery, with technology tailored to its complexity and precision.”
ORYOM™ from ForSight- A new era in ophthalmic robotics
The ORYOM™ Platform -named after the Hebrew word for “daylight” -integrates AI-driven algorithms, advanced computer vision, and ultra-precise micromechanics. The system enables surgeons to reach any point within the eye, from anterior to posterior segments, offering new levels of accuracy and control in complex procedures.
The platform has already been used by over two dozen surgeons in hundreds of procedures on animal eye models. Beyond cataracts, ForSight Robotics intends to extend its system to address retinal and glaucoma surgeries in future iterations.
Seth Winterroth, Partner at Eclipse, commented, “ForSight is tapping into a massive, underserved market with a breakthrough approach. Its potential to redefine global eye care is extraordinary.”
Scaling ForSight for global impact
Founded by Prof. Moshe Shoham, Dr. Daniel Glozman, and Dr. Joseph Nathan, ForSight Robotics has more than doubled its team to over 110 employees in the past year. The company also achieved ISO 13485:2016 certification, underlining its compliance with global quality standards for medical devices.
The startup has assembled a strategic advisory board that includes some of the most respected figures in surgical robotics. Dr. Fred Moll, founder of Intuitive Surgical and widely credited as the “father of surgical robotics,” recently joined ForSight’s board of directors. Other advisors include MAKO Surgical founder Rony Abovitz, as well as leading ophthalmologists such as Dr. David Chang and Prof. Boris Malyugin.
Founded in Israel, ForSight Robotics is developing the ORYOM™ Platform, the world’s first robotic system designed specifically for eye surgery. The company’s technology integrates artificial intelligence, computer vision, and advanced micromechanics to improve the precision, safety, and scalability of ophthalmic procedures. Backed by prominent investors and medical experts, ForSight aims to democratise access to high-quality eye care and address the global surgeon shortage.
